HistoIndex Partners with Houston Research Institute to Advance AI-Enabled MASH Diagnostics

HistoIndex, a pioneer in AI-driven digital pathology for chronic liver disease, has entered a strategic partnership with Houston Research Institute (HRI), a leading US clinical research organisation specialising in hepatology, gastroenterology, and metabolic liver disease.

The collaboration strengthens HistoIndex’s expanding network of commercial partnerships across the United States and Europe, aimed at improving diagnostic precision and clinical decision-making for patients with Metabolic Dysfunction–associated Steatohepatitis (MASH).

Expanding access to advanced MASH diagnostics

Through the partnership, all four HRI medical centres—

• Houston Research Institute Pasadena
• Houston Research Institute Sugar Land
• Houston Research Institute
• Houston Research Institute Medical Center

will gain access to HistoIndex’s integrated diagnostic offering, combining:

• Expert histopathological evaluation by experienced pathologists
• Advanced AI-based liver biopsy analysis

This approach enables more consistent, quantitative, and reproducible assessment of disease severity in MASH.

Introducing FibroSIGHT® Plus for quantitative fibrosis analysis

In addition to standard-of-care histological assessment of:

• Steatosis
• Lobular inflammation
• Ballooning
• Fibrosis

HistoIndex will provide FibroSIGHT® Plus, its proprietary AI-based diagnostic test. FibroSIGHT Plus delivers fully quantitative measurement of liver fibrosis from biopsy samples, addressing limitations of conventional categorical scoring systems commonly used in MASH diagnosis and clinical trials.

Improving clinical decision-making with AI

“Partnering with Houston Research Institute represents a significant step forward in our mission to bring quantitative, AI-enabled pathology into MASH clinical care,” said Dr. Yukti Choudhury, Chief Development Officer at HistoIndex.

“Our integrated diagnostic service centralises both traditional histopathology and AI-enhanced workflows, enabling faster turnaround times while maintaining rigorous quality standards across every specimen.”

Strengthening diagnostic capabilities at HRI

From the clinical perspective, the collaboration enhances diagnostic depth and consistency across HRI’s liver centres.

“This partnership expands our ability to offer advanced, high-quality diagnostic services to patients with MASH,” said Dr. Mazen Noureddin, MD, MHS, Director at Houston Research Institute and Co-Chairman of the Board at Summit and Pinnacle Clinical Research.

“Integrating expert histopathology with quantitative AI-based fibrosis analysis supports more informed clinical decision-making across our centres.”

Why this matters for MASH care and trials?

MASH is a progressive form of metabolic dysfunction–associated steatotic liver disease (MASLD) and can lead to:

• Advanced fibrosis
• Cirrhosis
• Liver failure
• Increased risk of liver cancer

While liver biopsy remains the diagnostic gold standard, categorical histological scoring systems often fail to capture the disease’s biological complexity and heterogeneity. This limitation has driven growing demand for AI-based digital pathology tools that provide more accurate, objective, and reproducible assessments—particularly in clinical trials and treatment response evaluation.

About HistoIndex

Founded in 2010, HistoIndex pioneers stain-free, fully automated imaging solutions for visualising and quantifying fibrosis in biological tissues.

By combining advanced biophotonic technology with AI-based analytics, the company delivers next-generation tools to improve disease assessment and drug efficacy evaluation in chronic liver disease.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!